Dated: January 14, 2003.

#### Margaret M. Dotzel,

Assistant Commissioner for Policy.
[FR Doc. 03–1256 Filed 1–17–03; 8:45 am]
BILLING CODE 4160–01–8

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Food and Drug Administration [Docket No. 00N-1526]

# Robert A. Fiddes; Debarment Order; Correction

AGENCY: Food and Drug Administration,

**ACTION:** Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of November 6, 2002 (67 FR 67628). The document announced the issuance of an order under the Federal Food, Drug, and Cosmetic Act debarring Dr. Robert A. Fiddes for 20 years from providing services in any capacity to a person that has an approved or pending drug product application. The document was published with an inadvertent error. This document corrects that error.

### FOR FURTHER INFORMATION CONTACT:

Joyce Strong, Office of Policy (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7010.

**SUPPLEMENTARY INFORMATION:** In FR Doc. 02–28256, appearing on page 67628 in the **Federal Register** of Wednesday, November 6, 2002, the following correction is made:

1. On page 67628, in the second column, under "II. Findings and Order", in the fourth and fifth lines, "(21 CFR 5.99)" is corrected to read "(21 CFR 5.34)".

Dated: January 14, 2003.

#### Margaret M. Dotzel,

Assistant Commissioner for Policy.
[FR Doc. 03–1255 Filed 1–17–03; 8:45 am]
BILLING CODE 4160–01–8

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Food and Drug Administration**

### Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on February 20, 2003, from 8:30 a.m. to 4:30 p.m.

Location: Ĥoliday Inn, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Jody G. Sachs or Denise H. Royster, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area), code 12391. Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will review and discuss the selection of strains to be included in the influenza virus vaccine for the 2003–2004 season and the intramural research program of the Laboratory of Bacterial Polysaccharides, Office of Vaccines Research and Review.

Procedure: On February 20, 2003, from 8:30 a.m. to 3:20 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 4, 2003. Oral presentations from the public will be scheduled between approximately 1 p.m. and 1:30 p.m. and 2:50 p.m. and 3:20 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 4, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 20, 2003, from 3:20 p.m. to 4:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)).

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Jody G. Sachs or Denise H. Royster at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 10, 2003.

#### Linda Arey Skladany,

Associate Commissioner for External Relations.

[FR Doc. 03–1208 Filed 1–17–03; 8:45 am] BILLING CODE 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of Inspector General; Program Exclusions: December 2002

**AGENCY:** Office of Inspector General, HHS.

**ACTION:** Notice of program exclusions.

During the month of December 2002, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusions is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and nonprocurement programs and activities.

Subject city, state	Effective date
PROGRAM-RELATED CONVICTIONS	
ALY, WAEL	01/20/2003
BACO-CUEBAS, GERMAN A MAYAGUEZ, PR	01/20/2003
BERG, SHANNON GRIFFIN FLORENCE. SC	01/20/2003
BRIDGER, BARBARA LYNN PIERRE. SD	01/20/2003
CHRISTOPHERSON, PAUL K	01/20/2003